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Abstract
Inflammatory bowel disease (IBD) with its two entities, ulcerative colitis and Crohn’s
disease, is at increased risk of developing colorectal cancer (CRC). Risk factors for CRC
are represented by the duration of the disease, extent of disease, the association of
primary sclerosing cholangitis, family history, and early age at onset. In inflammatory
bowel  disease,  colonic  carcinogenesis  appears  on  an  inflamed colon,  being  deter‐
mined by different genetic alterations. The main element of the process of carcinogen‐
esis is the dysplasia, which is a neoplastic intraepithelial transformation, limited to the
basal  membrane  surrounding  the  glands  around  which  it  appears.  The  stages  of
carcinogenesis process start with dysplasia of varying degrees as follows: indefinite
dysplasia, low-grade dysplasia, high-grade dysplasia, and finally invasive adenocarci‐
noma.
Endoscopic surveillance in IBD is absolutely necessary for early detection of dysplas‐
tic  lesions.  The endoscopic  surveillance  process  begins  after  7–10 years  of  disease
progression, performed every 1 or 2 years, depending on the severity of the disease.
General principles of endoscopic surveillance involve the use of modern diagnostic
methods (high definition, chromoendoscopy, indigo carmine with high definition, high-
definition narrow band imaging).
The current standard-of-care (colonoscopy plus randomized biopsies) to detect
dysplasia in IBD patients is inadequate. Guidelines now support to use of chromoen‐
doscopy with targeted biopsy in the detection of dysplasia and/or colorectal cancer in
patients with IBD.
Chemopreventive drugs involve the administration of therapeutic agents such as 5-
ASA derivatives, ursodeoxycholic acid and folic acid, and possibly statins.
As for future goals, understanding the mechanisms of colonic carcinogenesis in IBD can
identify patients at high risk for developing CRC and thus chemoprevention can be
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initiated. The discovery of new therapeutic agents plays an important role in chemo‐
prevention and represents a significant desideratum among researchers.
Keywords: colorectal cancer, inflammatory bowel disease, carcinogenesis, colono‐
scopic surveillance, chromoendoscopy, high-definition narrow band imaging
1. Introduction
Inflammatory bowel diseases with its two separate entities (ulcerative colitis and Crohn’s
disease) are conditions considered at high risk for developing colorectal cancer. Because
inflammatory bowel diseases are relatively rare in the general population, only about 1% of
colorectal cancers are attributed to them. Meta-analyzes showed that the risk is 2% at 10 years,
8% at 20 years, and 18% at 30 years after onset [1]. Absolute cumulative frequencies of
colorectal cancer to Crohn’s disease and ulcerative colitis are almost identical 7% for the first
to 8% for the second, after 20 years of evolution [2]. Most knowledge about the pathogenesis
of colorectal cancer come from studies on sporadic cancers or those associated with in‐
creased risk of hereditary disease (familial adenomatous polyposis or non-polyposis colorec‐
tal cancer), this data being then extrapolated for inflammatory bowel diseases.
Eaden et al. [3] reviewed 116 studies involving 55,000 patients with ulcerative colitis. One
thousand seven hundred of these patients developed colorectal cancer, having an incidence
of 2% after 10 years of evolution, and of 8% after 20 years finally increasing to 18% after 30
years.
2. Risk factors for colorectal cancer in inflammatory bowel disease
In ulcerative colitis, onset of colorectal cancer is correlated with many factors. Thus, the
duration of the disease is recognized as one of the leading risk factors for developing colorectal
cancer in ulcerative colitis. Neoplastic risk occurs after 8 years of evolution and increases
exponentially after 20 years [1].
A systematic colonoscopy surveillance can detect early dysplastic lesions, and the systematic
use of 5-ASA therapy can lower the risk of developing colorectal cancer in patients with IBD.
The reduced incidence of prophylactic colectomy for dysplastic lesions determines a high risk
for colorectal cancer. This information is an argument for preventive colonoscopy surveillance
of patients with IBD and surgical prophylaxis in case of dysplasia [4, 5].
Younger age at onset is in the opinion of some authors, an independent risk factor for colorectal
cancer. Younger patients have a potentially greater lifespan and therefore higher risks, which
may reflect the longer duration of the disease [1, 4–6]. The association of PSC increases the risk
of colorectal cancer. Its incidence in patients with ulcerative colitis is 2–5% [1]. In 1992, Broome
et al. reported an increased risk of colorectal cancer in patients with ulcerative colitis associ‐
Colorectal Cancer - From Pathogenesis to Treatment186
ating PSC. Subsequent studies have shown that the cumulative risk of colorectal cancer is
higher in patients with combination of cholangitis and ulcerative colitis compared with the
ones only known for ulcerative colitis, that is, 9% after 10 years compared to 2, 31% after 20
years compared to 5, and 50% after 25 years to 10% [7].
The extent of the disease is also an important risk factor for the risk of developing colorectal
cancer. Pancolitis presents the highest risk of malignancy [1]. The extension of inflammatory
areas is an independent risk factor involved in the carcinogenesis and Crohn’s disease.
A family history of colon cancer cancer is associated with an increased risk of colorectal −2 or
3 times higher, in the general population, which remains increased in patients with ulcerative
colitis. A case–control study conducted on 297 patients at the Mayo Clinic found that a family
history of sporadic colorectal cancer represents an independent risk factor for malignancy in
patients with ulcerative colitis [7].
An interesting finding is that patients with asymptomatic disease (therapeutically controlled)
have higher risks of malignancy compared with fulminant forms of ulcerative colitis that often
require colectomy before the onset of dysplasia. In centers where a large number of colectomies
are performed, the incidence of colorectal cancer (CRC) is significantly lower because the
procedure eliminates the risk [1].
In Crohn’s disease, the risk factors involved in carcinogenesis are areas of stenosis, inflamma‐
tory extension areas, younger age at onset and age >45 years at diagnosis. Risk factors specific
to patients with inflammatory bowel disease [8]:
• Coexisting primary sclerosing cholangitis
• Increasing cumulative extent of colonic inflammatory lesions
• Increasing duration of inflammatory bowel disease
• Active chronic inflammation endoscopically assessed
• Active chronic inflammation histologically assessed




• Personal history of flat dysplasia.
The severity of inflammatory colonic lesion correlates with the risk of colorectal cancer in
patients with IBD. There is a correlation between the degree of inflammation and the risk of
dysplastic lesions and indirectly with the colorectal cancer incidence. Various studies have
shown the relationship between the risk of colorectal cancer in patients with IBD and the degree
of inflammation, extent of lesions and coexistence of other sites of inflammation [9]. Involved
in the colonic carcinogenesis in patients with IBD are, besides inflammation areas of various
degrees, also genetic and immunological factors.
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3. Molecular and genetic markers
Pathogenesis of sporadic colon cancer and colitis-associated colon cancer [8].
Involved in the appearance of colorectal cancer associated with inflammatory bowel disease,
are, on the one hand the chromosomal instability caused by abnormal chromosome separation
(CRS) aneuploidy and loss of genetic material, and on the other hand, the microsatellite
instability (MSI) mechanisms found in sporadic carcinogenesis. The trigger element for
chromosomal instability is represented by impairing the function of APC associated with the
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induction of K-ras oncogene and inactivation of tumor suppressor gene on CRS 18q in DCC
and DPC4 region. Adenoma–carcinoma transformation is a direct result of the loss of p53 gene
function [1, 6, 8].
Microsatellite instability, which is absent on normal mucosa, is described as an early event in
non-dysplastic mucosa in patients with ulcerative colitis.
It is important to understand what mechanisms and factors can contribute to dysplastic lesions
and colorectal cancer in IBD. Inflammation and genetic mutations play a major role. The
supervision and therapeutic intervention in these disorders depends on understanding of
these pathological processes. Thus, some genes associated with inflammation such as cyclo‐
oxygenase-2, nitric oxide synthase-2, and 1–8 interferon inducible genes are increased in
inflamed colonic mucosa and remain elevated in colonic neoplasms [10, 11].
Genetic changes, responsible for colorectal cancer in inflammatory bowel disease, are similar
to those involved in sporadic colon cancer [8].
Oxidative stress and its role in cell destruction in inflamed tissue may also play an important
role in the pathogenesis of colorectal cancer in IBD [12].
Figures 1 and 2 depict some pathology aspects of colon mucosa with inflammatory changes.
The inflammatory context is suggested by an abundant lymphoplasmocitary infiltrate and
polimorphonucleated within the mucosal corion.
Figure 1. Inflammatory aspect of colonic mucosa. Modified cytoarchitectonics. Epithelial pseudostratification of the
glandular tissue.
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Figure 2. Inflammatory aspect of colonic mucosa. Nuclear pleomorphism. Mucus depletion, with a decreased number
of secretory cells within normal glands.
4. Prevention of colorectal cancer in inflammatory bowel disease
4.1. Endoscopic surveillance in IBD
Endoscopic surveillance in IBD is designed to detect dysplastic lesions that can be treated
surgically. As dysplastic lesions are difficult to recognize via endoscopic examination, their
detection requires colectomy that prevents colorectal cancer (CRC). This fact is also determined
by the risk of developing synchronous or metachronous cancer in IBD [13].
Colonoscopy surveillance reduces the risk of death from CRC in patients with long-term
evolution of inflammatory disease. Given the cost–benefit ratio, this surveillance is especially
recommended in patients with evolving active disease of over 7–10 years. The first colonoscopy
screening program will be carried out in a remission period of the disease to avoid difficulties
in identifying dysplasia in areas of increased inflammatory activity (Figures 3 and 4). The entire
colonic mucosa will be examined and four biopsies will be taken from 10 to 10 cm. Any
suspicious lesions will be biopsied. If the initial biopsy does not describe dysplastic foci, the
colonoscopy is recommended to be repeated after 2 years or annually if the disease has more
than 20 years of evolution when the risk of cancer increases exponentially. This interval is
reduced to 6 months, 1-year maximum if the pathology result of the lesions comes back as
indefinite dysplasia. The most controversial attitude is regarding mild dysplasia. In the case
of dysplastic lesions associated with IBD, there are opinions saying that endoscopic resection
can be done if the pathological examination of the fragments collected from the base of the
polyp and also from the colon are negative for dysplasia [14]. The marking of the polypectomy
site is recommended, and the colonoscopy should be repeated after 3–6 months. The confir‐
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mation of unifocal or multifocal dysplasia by a second expert requires that a colectomy should
be performed. High-grade dysplasia is an absolute indication for colectomy.
Figure 3. Ulcerative colitis with areas of low grade dysplasia.
Figure 4. Ulcerative colitis with high grade dysplasia.
There is an evolution of the inflammatory lesions that either do not have dysplastic lesions or
evolve from indefinite dysplasia to low-grade dysplasia, high-grade dysplasia, and finally
carcinoma.
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Dysplasia, detected at colonoscopic examination, represents an indication for colectomy.
When low-grade dysplasia is detected, it is considered that the risk of developing colorectal
cancer is nine times higher than in normal individuals and there is a 12 times higher risk of
developing other advanced dysplastic lesions.
In patients with low-grade dysplasia, when colectomy is performed immediately, it was noted
that 19% of the cases had high-grade dysplasia and 29–54% were at risk of developing
advanced neoplasia in the following 5 years. High-grade dysplasia has a risk of 43% of
combination with synchronous malignancy [14].
Dysplastic lesions are lesions that precede colorectal cancer development. Flat dysplasia can
be discovered through microscopic examination of biopsy fragments, collected through
random biopsies, sometimes from apparently normal mucosa. Often, flat dysplasia can be
discovered with superior detection techniques such as chromoendoscopy, high-definition, and
high magnification endoscopy [15–18].
Treatment for patients with dysplastic lesions and IBD depends on the degree of dysplasia.
Patients presenting with multifocal flat low-grade dysplasia lesions or repetitive flat low-grade
dysplasia should be advised to undertake prophylactic proctocolectomy.
Dysplasia-associated lesion or mass (DALM) is a specific endoscopic feature found in patients
with ulcerative colitis. DALM is associated in a proportion of 40% with colorectal cancer; this
Figure 5. Polipoid lesions in a patient suffering from Crohn’s disease.
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association is enhanced by the presence of high-grade dysplasia lesions. DALM is an indication
of proctocolectomy regardless of the degree of dysplasia.
Polypoid lesions identified in patients with IBD are not always malignant and can be treated
with endoscopic polypectomy, especially if the polyps are adenomatous [19] (Figure 5).
Dysplastic lesions detected in biopsy samples from patients with IBD usually occur in areas
of inflammation and can be polypoid, ulcerated lesions, or plague-like lesions (DALM). (Figure
6 describes various instances of lesions in a patient with IBD).
Figure 6. High grade dysplasia in a patient with Crohn’s disease.
Although prophylactic proctocolectomy ensures the elimination of the risk of colon cancer
(42% of cases in patients with high-grade dysplasia and 19% of cases in patients with low-
grade dysplasia), there are practitioners who opt for a lifelong schedule of surveillance. They
choose periodic examination at 6 months to 1 year by endoscopically investigating the entire
colon, harvesting biopsy fragments and using preventive treatment with anti-inflammatory
drugs and potentially chemopreventive agents. There are some major limitations to this
attitude, namely the possibility of omission of malignant or dysplastic lesions during colono‐
scopy, especially if the number of biopsies is insufficient. Also, the lack of compliance of
patients to colonoscopy surveillance programs is also an important risk factor for malignant
lesions.
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Guidelines from the Crohn’s and Colitis Foundation of America (CCFA) and from European
Crohn’s and Colitis Organization (ECCO) mention the same methods for Crohn’s colitis
surveillance and ulcerative colitis as well due to the similar risk of developing colorectal.
Colonoscopic screening is performed during remission of the disease, every 1 or 2 years, after
8–10 years of evolution. Screening interval may decrease with increasing duration of disease
progression. Patients with proctosigmoiditis, who have a lower risk of malignancy compared
to the general population, will be monitored using standard colorectal cancer prevention
measures.
Patients with PSC, who have an increased risk of malignancy, should be monitored annually.
Biopsy samples are collected from 10 to 10 cm (2–4 random biopsy specimens) and from suspect
areas. In addition, in ulcerative colitis, biopsies are harvested from every 5 cm from the rectum
and sigmoid, because the risk of developing colorectal cancer is higher in these regions. The
degree of detection of dysplastic lesions is higher if a greater number of randomized biopsies
are taken (90% if 33 and 95% if 56 random biopsies were taken) [20, 21].
4.2. New methods for early detection of dysplasia
To increase the rate of detection of dysplastic lesions, targeted biopsy represents an alternative.
Guidelines now support the use of chromoendoscopy with targeted biopsy in the detection of
dysplasia and/or colorectal cancer in patients with inflammatory bowel disease (IBD).
Chromoendoscopy can see injuries that are not visible in the white light of standard endoscopy.
Two substances are used, namely methylene blue and indigo carmine. High-magnification
chromoendoscopy increases the detection of dysplastic lesions 3–4.5 times over [22–26].
Because of these arguments chromoendoscopy is used for routine surveillance of patients with
IBD. With this method, the majority of dysplastic lesions can be discovered in patients with
IBD during surveillance colonoscopy. Using only conventional colonoscopy is obviously
insufficient in detecting dysplastic lesions [27–30].
Confocal laser endomicroscopy (CLE) is a modern technique for visualization of the histology
of colonic mucosa in real time, being extremely useful for diagnosing intraepithelial neoplasia.
With concomitant use of chromoendoscopic and CLE evaluation, the detection rate of dys‐
plastic lesions was increased by 4.75 times compared to classical colonoscopy [21, 28–30].
Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection of
intraepithelial neoplasia. Difficulties are caused by the high cost of exploration and biopsy
interpretation difficulty that often requires an experienced pathologist.
The use of narrow band imaging (NBI) is not superior to conventional colonoscopy in detecting
dysplastic lesions [31, 32].
Although many lesions can be identified by NBI, unfortunately equal numbers of dysplastic
lesions can be missed by both conventional colonoscopy and this method. More studies are
needed to clarify these issues.
We again underline that chromoendoscopy with targeted biopsy is indicated by all current
guidelines for detecting dysplastic lesions in IBD.
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4.3. Chemoprevention
Surveillance colonoscopy does not prevent colorectal cancer but allows early detection of
dysplastic lesions and surgical therapeutic intervention.
Treatment of inflammatory lesions of IBD with specific anti-inflammatory therapy represents
an important method of primary chemoprevention of colorectal cancer [33–36].
4.3.1. Aminosalicylates and other anti-inflammatory agents
IBD anti-inflammatory treatment in addition to relieving symptoms and improving lesions
can prevent dysplastic lesions and colorectal cancer. Although studies are contradictory, most
authors recommend administration of anti-inflammatory therapy for colorectal cancer
prevention [37].
5-aminosalicylic acid preparations (5-ASA) are the main anti-inflammatory drugs used for the
treatment of digestive tract inflammation in patients with IBD. Aminosalicylates inhibit
cyclooxygenase and 5-lipoxygenase, thus inhibiting the synthesis of leukotriene B4, throm‐
boxane A2 and prostaglandins and thus intervene in the immune response, reducing the
production of antibodies and phagocytic activity. The administration of 5-ASA preparations
reduces the risk of colorectal cancer, especially at higher doses of 2 g per day.
Mesalazine is effective in preventing colorectal cancer in IBD, proven experimentally on colon
cancer cell lines [38].
4.3.2. Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) used for treating PSC has a preventive effect in colorectal cancer
by decreasing the concentration of biliary acids in the colon and through its antioxidant
properties. On the other hand, it is unclear whether ursodeoxycholic acid is effective in
preventing colorectal cancer in patients with IBD without the association of primary sclerosing
cholangitis. In IBD forms associated with PSC, UDCA can reduce mortality and prevent the
evolution of dysplastic lesions [39].
Further studies are necessary to establish the dose of UDCA to be used for secondary chemo‐
prevention.
4.3.3. Folic acid
There are numerous studies showing that as in sporadic CRC, folic acid supplementation
would decrease the risk of CRC in patients with IBD. Although there is no consensus in this
regard, given that it is a cheap drug, that offers long-term safety, folic acid is recommended in
patients with IBD as chemopreventive purposes. The mechanism of action is possibly related
to the process of maintenance of DNA methylation and maintenance of DNA precursors level.




There is little data on the protective effect of statins on the development of CRC. It seems that
the protective effect is lower in sporadic colorectal cancer and more expressed in colorectal
cancer associated with inflammatory bowel disease. Experimental studies on mice show the
protective effect of statins in reducing colorectal Dysplasia by inhibiting DNA destruction.
Also in experimental models simvastatin significantly reduced tumor development by
inducing apoptosis and inhibiting angiogenesis [40, 41].
These experiments provide important arguments that statins could be a potential chemopre‐
ventive and therapeutic agent effective in CRC associated with IBD. Extensive studies over
long periods of time are needed to bring new arguments and insights on these aspects.
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